49 results on '"García-Sánchez V"'
Search Results
2. P845 Impact of Clostridium difficile infection in patients admitted with ulcerative colitis
3. Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study
4. P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
5. P008 Proteomic markers of response to anti-TNF drugs in patients with Crohn's disease
6. Post-Operative Morbidity and Mortality of a Cohort of Steroid Refractory Acute Severe Ulcerative Colitis: Nationwide Multicenter Study of the GETECCU ENEIDA Registry
7. P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU
8. P237 Value of 75SeHCAT in the diagnosis of bile acid malabsorption in Crohn’s Disease with chronic diarrhoea
9. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
10. P270 Bile acid malabsorption incidence and diagnosis in clinical practice
11. P391 The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry
12. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989–2013): A Nationwide Multicenter Study
13. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry
14. P607 Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide study
15. P545 Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results
16. P327 Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study
17. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
18. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab
19. Síndrome de Mayer-Rokitansky-Küster-Hauser: a propósito de un caso
20. Comentarios a artículos sobre la enfermedad de Crohn
21. Letter: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease
22. P372 Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients
23. DOP051 Usefulness of a faecal calprotectin rapid semiquantitative test in predicting relapse in patients with ulcerative colitis in remission
24. P396 Outcomes of surgical treatment of entero-urinary fistulas in Crohn's disease
25. P646 Clinical and epidemiological features of patients with inflammatory bowel disease and extraintestinal manifestations associated
26. P665 A genome-wide association study identifies DSE-FAM26F as a risk locus for ulcerative colitis
27. POLIPECTOMÍA DE PÓLIPOS GÁSTRICOS. ESTUDIO RETROSPECTIVO DE UNA SERIE DE 20 AÑOS
28. Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease
29. Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease
30. P425 One-year outcomes of ustekinumab therapy in a multi-drug refractory Crohn's disease cohort
31. P531 Effectiveness of anti-TNF agents in the treatment of entero-urinary fistulas in Crohn's disease
32. P650 Entero-urinary fistulas in Crohn's disease: prevalence and clinical manifestations
33. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease
34. P407 Phenotypic concordance in familial inflammatory bowel disease (IBD)
35. P408 Safety of immunomodulators and anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy
36. P156 Development of quality standards for the management of inflammatory bowel disease by nurses: Perspectives of professionals and patients
37. P102 Process standards for the management of inflammatory bowel disease by nurses: Perspectives from health professionals and patients
38. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease
39. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
40. Prematuridad con parálisis cerebral y ceroidolipofuscinosis
41. Costes médicos directos de la enfermedad de Crohn en España
42. LA DETERMINACIÓN DE LA TPMT EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL: ¿ES UNA ESTRATEGIA COSTE-EFECTIVA EN PACIENTES QUE COMIENZAN TRATAMIENTO CON TIOPURINAS?
43. ¿PODEMOS IDENTIFICAR PACIENTES CON EII CON ALTO RIESGO DE RECIDIVA EN FUNCIÓN DE SUS CARACTERÍSTICAS CLÍNICAS Y PARÁMETROS DE LABORATORIO CONVENCIONAL?
44. EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON ADALIMUMAB EN LOS PACIENTES CON ENFERMEDAD DE CROHN: EXPERIENCIA EN NUESTRO CENTRO
45. RELEVANCIA DE LA CARGA FAMILIAR EN UN PROGRAMA DE PREVENCIÓN DE CÁNCER COLORRECTAL OFERTADO A FAMILIARES DE PRIMER GRADO
46. ¿PUEDEN LAS CITOQUINAS SISTÉMICAS PREDECIR LA RECIDIVA DE LA ENFERMEDAD INFLAMATORIA INTESTINAL?
47. LA CALPROTECTINA FECAL, ¿PREDICE LA RECIDIVA DE LOS PACIENTES CON ENFERMEDAD DE CROHN Y COLITIS ULCEROSA?
48. Enfermedad de Crohn perianal
49. Self-inflicted burns
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.